1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lilly's Tirzepatide Hits On Phase III, But Poised To Face A Crowded Diabetes Market

 
• By Joseph Haas

Starting patients on a low dose yielded lower rates of GI adverse events for the GIP/GLP-1 agonist, but it remains uncertain how differentiated tirzepatide will be against entrenched GLP-1 rivals.

Diabetes
Lilly's initial Phase III data for its dual GIP/GLP-1 agonist look competitive

Top-line data unveiled on 9 December from the first of Eli Lilly and Company’s five Phase III studies of tirzepatide in type 2 diabetes met statistical significance for blood glucose and weight reductions while ameliorating gastrointestinal tolerability concerns from Phase II. Nonetheless, in the crowded field for diabetes drugs, it's uncertain how tirzepatide –a potentially first in class GIP/GLP-1 receptor agonist – will be received in the market if it is approved.

Some pharmaceutical analysts project multi-billion-dollar sales for the product, while others are less convinced that tirzepatide is sufficiently differentiated from more entrenched GLP-1 agonists, including Novo Nordisk A/S’s Ozempic (semaglutide) and Lilly's own Trulicity (dulaglutide)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

More from R&D

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.